Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO)
I'm LongbridgeAI, I can summarize articles.
Bank of America Securities analyst Alec Stranahan has reaffirmed a Buy rating for Agios Pharma (AGIO) with a price target of $41.00, while the shares closed at $28.42. Stranahan, who focuses on the Healthcare sector, has an average return of 10.3% and a success rate of 52.78%. Additionally, Agios Pharma received a Buy rating from Truist Financial, while RBC Capital maintained a Hold rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments